Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report

S. C. Sung, S. R. Wisniewski, G. K. Balasubramani, S. Zisook, B. Kurian, D. Warden, M. H. Trivedi, A. J. Rush

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation. Whether these patients have poorer response to various types of antidepressant treatment than those with adult-onset MDD is unclear. Method A total of 665 psychiatric and primary care out-patients (aged 18-75 years) with non-psychotic chronic or recurrent MDD participated in a single-blind, randomized trial that compared the efficacy of escitalopram plus placebo, bupropion sustained-release plus escitalopram, or venlafaxine extended-release plus mirtazapine. We compared participants who self-reported MDD onset (before age 18) to those with a later onset (adult onset) with respect to baseline characteristics and treatment/outcome variables at 12 and 28 weeks. Results Early-onset chronic/recurrent MDD was associated with a distinct set of sociodemographic (female, younger age) and clinical correlates (longer duration of illness, greater number of prior episodes, greater likelihood of atypical features, higher rates of suicidality and psychiatric co-morbidity, fewer medical problems, poorer quality of life, greater history of child abuse/neglect). However, results from unadjusted and adjusted analyses showed no significant differences in response, remission, tolerability of medications, quality of life, or retention at 12 or 28 weeks. Conclusions Although early-onset chronic/recurrent MDD is associated with a more severe clinical picture, it does not seem to be useful for predicting differential treatment response to antidepressant medication. Clinicians should remain alert to an increased risk of suicidality in this population.

Original languageEnglish (US)
Pages (from-to)945-960
Number of pages16
JournalPsychological Medicine
Volume43
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Major Depressive Disorder
Carbon Monoxide
Antidepressive Agents
Depression
Citalopram
Child Abuse
Psychiatry
Quality of Life
Bupropion
Suicidal Ideation
Age of Onset
Primary Health Care
Outpatients
Placebos
Morbidity
Therapeutics
Population

Keywords

  • Age-of-onset
  • chronic
  • depression
  • early-onset
  • recurrent

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Applied Psychology

Cite this

Sung, S. C., Wisniewski, S. R., Balasubramani, G. K., Zisook, S., Kurian, B., Warden, D., ... Rush, A. J. (2013). Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report. Psychological Medicine, 43(5), 945-960. https://doi.org/10.1017/S0033291712001742

Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report. / Sung, S. C.; Wisniewski, S. R.; Balasubramani, G. K.; Zisook, S.; Kurian, B.; Warden, D.; Trivedi, M. H.; Rush, A. J.

In: Psychological Medicine, Vol. 43, No. 5, 05.2013, p. 945-960.

Research output: Contribution to journalArticle

Sung, S. C. ; Wisniewski, S. R. ; Balasubramani, G. K. ; Zisook, S. ; Kurian, B. ; Warden, D. ; Trivedi, M. H. ; Rush, A. J. / Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report. In: Psychological Medicine. 2013 ; Vol. 43, No. 5. pp. 945-960.
@article{bb3ab6401a484ebe86e31056e1b93029,
title = "Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report",
abstract = "Background Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation. Whether these patients have poorer response to various types of antidepressant treatment than those with adult-onset MDD is unclear. Method A total of 665 psychiatric and primary care out-patients (aged 18-75 years) with non-psychotic chronic or recurrent MDD participated in a single-blind, randomized trial that compared the efficacy of escitalopram plus placebo, bupropion sustained-release plus escitalopram, or venlafaxine extended-release plus mirtazapine. We compared participants who self-reported MDD onset (before age 18) to those with a later onset (adult onset) with respect to baseline characteristics and treatment/outcome variables at 12 and 28 weeks. Results Early-onset chronic/recurrent MDD was associated with a distinct set of sociodemographic (female, younger age) and clinical correlates (longer duration of illness, greater number of prior episodes, greater likelihood of atypical features, higher rates of suicidality and psychiatric co-morbidity, fewer medical problems, poorer quality of life, greater history of child abuse/neglect). However, results from unadjusted and adjusted analyses showed no significant differences in response, remission, tolerability of medications, quality of life, or retention at 12 or 28 weeks. Conclusions Although early-onset chronic/recurrent MDD is associated with a more severe clinical picture, it does not seem to be useful for predicting differential treatment response to antidepressant medication. Clinicians should remain alert to an increased risk of suicidality in this population.",
keywords = "Age-of-onset, chronic, depression, early-onset, recurrent",
author = "Sung, {S. C.} and Wisniewski, {S. R.} and Balasubramani, {G. K.} and S. Zisook and B. Kurian and D. Warden and Trivedi, {M. H.} and Rush, {A. J.}",
year = "2013",
month = "5",
doi = "10.1017/S0033291712001742",
language = "English (US)",
volume = "43",
pages = "945--960",
journal = "Psychological Medicine",
issn = "0033-2917",
publisher = "Cambridge University Press",
number = "5",

}

TY - JOUR

T1 - Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report

AU - Sung, S. C.

AU - Wisniewski, S. R.

AU - Balasubramani, G. K.

AU - Zisook, S.

AU - Kurian, B.

AU - Warden, D.

AU - Trivedi, M. H.

AU - Rush, A. J.

PY - 2013/5

Y1 - 2013/5

N2 - Background Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation. Whether these patients have poorer response to various types of antidepressant treatment than those with adult-onset MDD is unclear. Method A total of 665 psychiatric and primary care out-patients (aged 18-75 years) with non-psychotic chronic or recurrent MDD participated in a single-blind, randomized trial that compared the efficacy of escitalopram plus placebo, bupropion sustained-release plus escitalopram, or venlafaxine extended-release plus mirtazapine. We compared participants who self-reported MDD onset (before age 18) to those with a later onset (adult onset) with respect to baseline characteristics and treatment/outcome variables at 12 and 28 weeks. Results Early-onset chronic/recurrent MDD was associated with a distinct set of sociodemographic (female, younger age) and clinical correlates (longer duration of illness, greater number of prior episodes, greater likelihood of atypical features, higher rates of suicidality and psychiatric co-morbidity, fewer medical problems, poorer quality of life, greater history of child abuse/neglect). However, results from unadjusted and adjusted analyses showed no significant differences in response, remission, tolerability of medications, quality of life, or retention at 12 or 28 weeks. Conclusions Although early-onset chronic/recurrent MDD is associated with a more severe clinical picture, it does not seem to be useful for predicting differential treatment response to antidepressant medication. Clinicians should remain alert to an increased risk of suicidality in this population.

AB - Background Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation. Whether these patients have poorer response to various types of antidepressant treatment than those with adult-onset MDD is unclear. Method A total of 665 psychiatric and primary care out-patients (aged 18-75 years) with non-psychotic chronic or recurrent MDD participated in a single-blind, randomized trial that compared the efficacy of escitalopram plus placebo, bupropion sustained-release plus escitalopram, or venlafaxine extended-release plus mirtazapine. We compared participants who self-reported MDD onset (before age 18) to those with a later onset (adult onset) with respect to baseline characteristics and treatment/outcome variables at 12 and 28 weeks. Results Early-onset chronic/recurrent MDD was associated with a distinct set of sociodemographic (female, younger age) and clinical correlates (longer duration of illness, greater number of prior episodes, greater likelihood of atypical features, higher rates of suicidality and psychiatric co-morbidity, fewer medical problems, poorer quality of life, greater history of child abuse/neglect). However, results from unadjusted and adjusted analyses showed no significant differences in response, remission, tolerability of medications, quality of life, or retention at 12 or 28 weeks. Conclusions Although early-onset chronic/recurrent MDD is associated with a more severe clinical picture, it does not seem to be useful for predicting differential treatment response to antidepressant medication. Clinicians should remain alert to an increased risk of suicidality in this population.

KW - Age-of-onset

KW - chronic

KW - depression

KW - early-onset

KW - recurrent

UR - http://www.scopus.com/inward/record.url?scp=84875936452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875936452&partnerID=8YFLogxK

U2 - 10.1017/S0033291712001742

DO - 10.1017/S0033291712001742

M3 - Article

C2 - 23228340

AN - SCOPUS:84875936452

VL - 43

SP - 945

EP - 960

JO - Psychological Medicine

JF - Psychological Medicine

SN - 0033-2917

IS - 5

ER -